Acamprosate ( DrugBank: Acamprosate )
2 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 1 |
206 | 脆弱X症候群 | 3 |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00640952 (ClinicalTrials.gov) | August 2006 | 28/12/2007 | Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease | Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease | Parkinson's Disease | Drug: acamprosate | Baylor College of Medicine | National Parkinson Foundation | Withdrawn | 18 Years | N/A | Both | 0 | N/A | United States |
206. 脆弱X症候群
臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02998151 (ClinicalTrials.gov) | January 2016 | 1/12/2016 | Neurophysiological and Acute Pharmacological Studies in FXS Patients | Neurophysiological and Acute Pharmacological Studies in FXS Patients | Fragile X Syndrome | Drug: Acamprosate;Drug: Lovastatin;Drug: Minocycline;Drug: Placebo;Drug: Baclofen | Children's Hospital Medical Center, Cincinnati | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | 15 Years | 55 Years | All | 29 | Early Phase 1 | United States |
2 | NCT01911455 (ClinicalTrials.gov) | August 27, 2013 | 26/7/2013 | Study of Acamprosate in Fragile x Syndrome | Double-Blind, Placebo-Controlled Proof of Concept Study in Youth With Fragile X Syndrome | Fragile X Syndrome | Drug: acamprosate;Drug: Placebo | Children's Hospital Medical Center, Cincinnati | Rush University Medical Center | Completed | 5 Years | 23 Years | All | 46 | Phase 1 | United States |
3 | NCT01300923 (ClinicalTrials.gov) | August 2010 | 25/8/2010 | Acamprosate in Youth With Fragile X Syndrome | Pilot Study of Acamprosate in Youth With Fragile X Syndrome | Fragile X Syndrome;Autism Spectrum Disorders | Drug: Acamprosate | Indiana University | NULL | Completed | 5 Years | 17 Years | All | 14 | Phase 2 | United States |